SANTA ANA, CA / ACCESSWIRE / August 25, 2015 / BioLargo, Inc. (BLGO) announced today that it had conducted its first annual confidential technical symposium August 17th at its laboratory on the University of Alberta campus in Edmonton Canada. Over 30 individuals representing a wide range of interested stakeholder groups including science, research, academia, industry, engineering, federal and provincial funding agencies, investment professionals and a leading global philanthropic organization attended. BioLargo scientists presented results of experiments and studies validating the company's technical claims that the AOS Filter is less than 1/20th the cost of the nearest technical competitor, at greater than 100 times the efficacy (disinfection), and more than 10 times faster. Researchers presented confirmation of more than 100 studies replicating these findings, demonstrating the AOS Filter's important role and high value in just about every segment of the global water industry estimated at $350 billion annually.
Independent researchers refer to the AOS Filters disinfection rates of performance as "unprecedented". The AOS Filter combines iodine, water filter materials and electrolysis within a flow-through water filter device, generating extremely high oxidation that eliminates soluble organic contaminants that are commonly found in many types of contaminated water. Studies prove extremely high rates of disinfection, eliminating infectious biological pathogens like Salmonella, Listeria and E.coli in water.
Symposium attendees were able to see multiple working AOS Filters, including a design of sufficient scale designed to serve the poultry processing industry.
Walter L. Schindler, a Strategic Advisor to BioLargo, a pioneer in clean tech investing, and founder of Sail Capital Partners, commented, "This conference was an exciting experience for those of us committed to sustainability in new water technology. All day long we heard scientists present the consistent results of their tests of the BioLargo water technology, which validated the extraordinary speed, high impact and low energy consumption of the path-breaking innovation."
Richard Smith, President of BioLargo Water commented, "We have assembled an extraordinary team of professional researchers and the interest and excitement in our technology is expanding rapidly. We have a number of new scientific collaborations, additional research funding commitments to announce in the near future. We are exceedingly grateful for the continued financial support from various federal, provincial and industrial sponsors."
Dennis P. Calvert, President & CEO of BioLargo commented, "The numerous scientific studies at the University of Alberta have established that BioLargo has developed the world's highest impact, lowest cost, fastest acting water technology for disinfection and decontamination of wastewater from any source."
About BioLargo, Inc.
BioLargo, Inc. (BLGO) makes life better by delivering technology-based products that help solve some of the world's most important problems that threaten water, food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. The subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS Filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies, It is the winner of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil industry. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project. The subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution(R) and Deodorall(R) brands. (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2016.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2014.
SOURCE: BioLargo, Inc.